ATNT-01 ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY

Documenti analoghi

• ET-19 A PHASE 1 STUDY EVALUATING ABT-414 WITH TEMOZOLOMIDE (TMZ) OR CONCURRENT RADIOTHERAPY (RT) AND TMZ IN GLIOBLASTOMA (GBM)
  di: Gan, Hui K., et al.
  Pubblicazione: (2014)
• ATNT-02 DETERMINANTS OF RESPONSES AND RESISTANCE TO ABT-414: RESULTS OF NEXT-GENERATION SEQUENCING
  di: Scott, Andrew M., et al.
  Pubblicazione: (2015)
• Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
  di: Reardon, David A., et al.
  Pubblicazione: (2017)
• P09.25 Identifying the correct patient (pt) population for ABT414: biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)
  di: Lassman, A., et al.
  Pubblicazione: (2017)
• PATH-29. MOLECULAR DETERMINANTS ASSOCIATED WITH RESPONSE AND RESISTANCE TO DEPATUXIZUMAB MAFODOTIN (ABT-414) IN PATIENTS WITH RECURRENT GLIOBLASTOMA
  di: Lassman, Andrew, et al.
  Pubblicazione: (2017)